Aurobindo Pharma Limited
F&O₹1,666.90▼ -11.00 (-0.66%)
AUROPHARMA·NSE·Healthcare
Market Cap
95512.73 Cr
PE Ratio
27.63
Volume
7,96,657
Day High - Low
1681.70 - 1655.00
52W High-Low
1740.00 - 1080.10
₹1,666.90▼ -11.00 (-0.66%)
Market Cap95512.73 Cr
PE Ratio27.63
Volume7,96,657
Day High - Low1681.70 - 1655.00
52W High-Low1740.00 - 1080.10
Aurobindo Pharma Limited (AUROPHARMA): company summary
The company's annual revenue rose 6.1% to ₹33,653 crore, while annual net profit grew 0.6% to ₹3,503 crore.
Aurobindo Pharma Limited (AUROPHARMA) is a mid-cap Healthcare company valued at ₹95,513 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Aurobindo Pharma Limited last traded at ₹1,666.9, modestly down 0.66% on the day.
- Recent developments
- On 2026-10-03, Aurobindo Pharma received USFDA final approval for Perampanel tablets, set to launch in Q3 FY27 with an estimated US market size of $67 million. On 2026-10-01, the company announced an acquisition and launched Adquey in the US, with Nuvama projecting $300 million peak sales. On 2026-09-30, Acrotech, Aurobindo's US subsidiary, launched Adquey and established a dedicated dermatology business unit.
- Financial performance
- The company's annual revenue rose 6.1% to ₹33,653 crore, while annual net profit grew 0.6% to ₹3,503 crore. The latest quarter saw revenue rise 16.3% year-on-year to ₹9,150 crore and net profit jump 25.2% to ₹1,032 crore, outpacing the prior year's quarter. However, the net profit margin narrowed 0.6 percentage points to 10.4%, and return on equity remained flat at 9.2%.
- Valuation multiples
- The stock trades at 27.6 times earnings, broadly in line with the Healthcare median of 32.0, 2.53 times book value. It yields 0.2%.
- Things to watch
- The stock is 4.2% below its 52-week high. Promoter shares pledged account for 11.99% of promoter holding. Domestic institutional holding fell 0.68 points in the quarter. The net profit margin narrowed 0.6 percentage points to 10.4%.
- Where it stands
- Aurobindo Pharma's latest quarter revenue and net profit rose 16.3% and 25.2% year-on-year, respectively, while annual revenue and net profit grew 6.1% and 0.6%. The net profit margin narrowed to 10.4%, and the stock is 4.2% below its 52-week high. Promoter shares pledged account for 11.99% of promoter holding.
Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.9/10
Weak
Fair Value
Sign in to see
ROE
9.25%
Average
P/E
27.63x
Fair
Debt / Equity
0.21
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
NIFTY 200NIFTY 500NIFTY MIDCAP 150
Day₹1655
₹1682
52W₹1080
₹1740
DocStoX take
Supported by risk (9.0) and momentum (7.5), but held back by growth (1.3). Risk looks strong at 9.0, but that is offset by growth at 1.3 and valuation at 2.6. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.9
/10
Weak
Quality
Solid
ROE 9.2%
Valuation
Expensive
P/E 27.6×
Growth
Flat
Revenue +6.3% 5Y CAGR
Risk
Low risk
D/E 0.21
Momentum
Strong
89% of 52-week range
At a glance
Market Cap
₹95,513 Cr
52W High / Low
₹1740 / ₹1080
Dividend Yield
0.24%
Promoter Holding
51.88%
EPS (TTM)
₹60.34
Book Value
₹652.39
Key highlights
- Low leverage — D/E 0.21
- Profitable in all of the last 5 years
- Profit shrinking 8% a year
- Growth is weak (1.3/10)
2 Positives2 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Aurobindo Pharma Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Aurobindo Pharma Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises LimitedMax Healthcare Institute Limited
Compare Aurobindo Pharma Limited with peers
Aurobindo Pharma Limited vs Sun Pharmaceutical Industries LimitedAurobindo Pharma Limited vs Divi's Laboratories LimitedAurobindo Pharma Limited vs Torrent Pharmaceuticals LimitedAurobindo Pharma Limited vs Apollo Hospitals Enterprise LimitedAurobindo Pharma Limited vs Zydus Lifesciences LimitedAurobindo Pharma Limited vs Laurus Labs Limited
Related tools & concepts
Value Aurobindo Pharma Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing